All intercompany accounts and transactions have been eliminated in consolidation.
Changes in estimates are recorded in the period in which they occur and become known.
Net foreign currency transaction and remeasurement losses totaled $0.6 million and $0.7 million, respectively, during the three months ended June 30, 2018 and 2017, and $3.1 million and $1.6 million, respectively, during the nine months ended June 30, 2018 and 2017.
The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations.
The forward contract arrangements that the Company enters into, typically mature in three months or less.
These transactions do not qualify for hedge accounting.
The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.
The Company expects to adopt the guidance during the first quarter of fiscal year 2020 and is evaluating the effect that ASU 2018-02 will have on its consolidated financial statements and related disclosures.
The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018 and should be adopted via a modified retrospective approach with certain optional practical expedients that entities may elect to apply.
The new guidance introduces a new "expected loss" impairment model that applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and other financial assets.Item 2.
·    Overview.
·    Critical Accounting Policies and Estimates.
anticipated or unanticipated events.
In April 2018, we acquired BioSpeciMan Corporation, or BioSpeciMan, a Canadian provider of storage services for biological sample materials.
Please refer to Note 4, “Acquisitions” in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10‑Q for further information on these transactions.
In fiscal year 2017, we launched BioStudies, a bioinformatics sample intelligence software platform that enables customers to manage their global samples.
Results of Operations- Revenue for the three months ended June 30, 2018 increased to $223.5 million, or by 23%, as compared to the corresponding period of the prior fiscal year.